Clinical Trial Update: SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update describes evaluating SBRT in combination with anlotinib and bimepolizumab for locally advanced or metastatic renal cell carci…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Bimepolizumab (bimepolizumab)

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Locally Advanced or Metastatic Renal Cell Carcinoma | Phase 2 | Status: NOT_YET_RECRUITING